Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Biliary Tract Cancer: A Randomized and Exploratory Cohort, Open-label, Multicenter, Phase II Study

NCT06465563 is registered in ClinicalTrials.gov with Suzhou Suncadia Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT06465563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy for the First-Line Treatment of Advanced Biliary Tract Cancer: A Randomized and Exploratory Cohort, Open-label, Multicenter, Phase II Study
Lead sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 1, 2024
Completion date
December 30, 2026
Enrollment
93 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancer